Market Cap (In SEK)
287.49 Million
Revenue (In SEK)
721 Thousand
Net Income (In SEK)
-37.07 Million
Avg. Volume
449.51 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.503-4.885
- PE
- -6.59
- EPS
- -0.27
- Beta Value
- 1.886
- ISIN
- SE0009581051
- CUSIP
- -
- CIK
- -
- Shares
- 161515000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Petter Segelman Lindqvist
- Employee Count
- -
- Website
- https://isofolmedical.com
- Ipo Date
- 2017-04-04
- Details
- Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
More Stocks
-
LGMH
-
8430C&N Holdings Limited
8430
-
JSWHLJSW Holdings Limited
JSWHL
-
SEXHF
-
348340Neuromeka Co., Ltd.
348340
-
ARNOLDArnold Holdings Ltd.
ARNOLD
-
603042
-
3283